Status:
COMPLETED
Citrate Dialysate in Online Hemodialfiltration
Lead Sponsor:
Bangkok Metropolitan Administration Medical College and Vajira Hospital
Conditions:
Hemodiafiltration
Heparin
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Online hemodiafiltration (Ol-HDF) is increasingly being used for patients on chronic dialysis due to in its superiority compared with standard hemodialysis HDF. In addition to an excellent clearance o...
Detailed Description
Heparin is the most routinely used anticoagulant in hemodialysis. However, it exposes the patient to the risk of bleeding complications and can induce thrombocytopenia. Furthermore, long-term use of h...
Eligibility Criteria
Inclusion
- Stable condition
- Having been under HD for at least three months
- he vascular access should have blood flow ≥ 300 mL/min.
Exclusion
- no heparin use during HD
- refusal to participate,
- intolerance or allergy to citrate
- concurrent infection
- poor life expectancy due to metastatic cancer, severe cirrhosis and AIDS.
- patients vascular access modification,
- patients affected by chronic liver disease, active neoplastic or inflammatory disease were excluded as well as patients receiving immunosuppressive or anti-inflammatory drugs.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT05280106
Start Date
February 1 2022
End Date
September 30 2022
Last Update
February 8 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine ,Vajira hospital,Navamindradhiraj University
Bangkok, Thailand, 10300
2
Faculty of Medicine ,Vajira Hospital
Bangkok, Thailand, 10300